Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Personalis, Inc.
  6. Company
    PSNL   US71535D1063

PERSONALIS, INC.

(PSNL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Personalis, Inc.
Personalis, Inc. is a cancer genomics company. The Company is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The Company provides sequencing and data analysis services to support the development of cancer therapies. The Company has designed NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. It also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.

Number of employees : 235 people.
Sales per Business
20192020Delta
United States Veterans Affair's Million Veteran Program43.5566.8%56.1571.4% +28.96%
All Other Customers21.6633.2%22.4928.6% +3.84%
USD in Million
Sales per region
20192020Delta
United States62.6096%74.7295% +19.36%
International2.614%3.935% +50.77%
USD in Million
Managers
Name Title Age Since
John S. West President, Chief Executive Officer & Director 64 2011
Aaron Tachibana Chief Financial Officer 60 2019
Richard O. Chen, Dr. Chief Scientific Officer 50 2011
Xavier Paliard, Dr. Vice President-Immunology, Research & Development - 2017
Carol J. Tillis Vice President-Finance & Administration - 2011
Jonathan J. MacQuitty, Dr. Chairman 68 -
Kenneth E. Ludlum Independent Director 67 2015
Arthur Blaine Bowman Independent Director 74 2019
Alan B. Colowick, Dr. Independent Director 58 2019
Paul A. Ricci Independent Director 64 2019
Members of the board
Name Title Age Since
Jonathan J. MacQuitty, Dr. Chairman 68 -
John S. West President, Chief Executive Officer & Director 64 2011
Kenneth E. Ludlum Independent Director 67 2015
Arthur Blaine Bowman Independent Director 74 2019
Alan B. Colowick, Dr. Independent Director 58 2019
Paul A. Ricci Independent Director 64 2019
Karin Eastham Independent Director 71 2019
Woodrow A. Myers, Dr. Independent Director 67 2021
Shareholders
NameEquities%
Lightspeed Management Co. LLC 7,928,531 17.7%
ARK Investment Management LLC 5,165,360 11.5%
Abingworth LLP 4,462,452 9.96%
JPMorgan Investment Management, Inc. 2,943,976 6.57%
The Vanguard Group, Inc. 1,876,156 4.19%
Swedbank Robur Fonder AB 1,297,000 2.90%
Marshall Wace LLP 1,292,248 2.89%
JPMorgan Asset Management (UK) Ltd. 1,160,597 2.59%
Nikko Asset Management Co., Ltd. 1,085,026 2.42%
Nikko Asset Management Americas, Inc. 1,085,026 2.42%
Company contact information
Personalis, Inc.
1330 O'Brien Drive
Menlo Park, CA 94025

Phone : +1.650.752.1300
Fax : +1.650.752.1301
Web : http://www.personalis.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Personalis, Inc.